Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

Key Points

• The aim is to evaluate the efficacy of inhaled treprostinil for improving lung function in patients with idiopathic pulmonary fibrosis (IPF).
• Conducted a 52-week clinical trial comparing inhaled treprostinil with placebo.
• Measured forced vital capacity (FVC) as a primary outcome.
• Documented clinical worsening events.
• Inhaled treprostinil resulted in a smaller decline in FVC compared to placebo.
• Fewer clinical worsening events were observed in the treprostinil group than in the placebo group.